Small-molecule inhibitors targeting Axl render HNSCC cell lines more sensitive towards radiation, chemotherapy, cetuximab, and PARP-inhibition [20,24,26,27] but it also has to be considered that the upregulation of other TAM receptors may again induce resistance [30]. The gene discussed is AXL; the disease is head and neck squamous cell carcinoma.